MX354965B - Metodo para mejorar la funcion del diafragma. - Google Patents

Metodo para mejorar la funcion del diafragma.

Info

Publication number
MX354965B
MX354965B MX2014011881A MX2014011881A MX354965B MX 354965 B MX354965 B MX 354965B MX 2014011881 A MX2014011881 A MX 2014011881A MX 2014011881 A MX2014011881 A MX 2014011881A MX 354965 B MX354965 B MX 354965B
Authority
MX
Mexico
Prior art keywords
methods
skeletal muscle
diaphragm
patient
function
Prior art date
Application number
MX2014011881A
Other languages
English (en)
Spanish (es)
Other versions
MX2014011881A (es
Inventor
Malik Fady
R Jasper Jeffrey
T Hwee Darren
Original Assignee
Cytokinetics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cytokinetics Inc filed Critical Cytokinetics Inc
Publication of MX2014011881A publication Critical patent/MX2014011881A/es
Publication of MX354965B publication Critical patent/MX354965B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Pulmonology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Toxicology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
MX2014011881A 2012-04-02 2013-04-01 Metodo para mejorar la funcion del diafragma. MX354965B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261619261P 2012-04-02 2012-04-02
PCT/US2013/034824 WO2013151938A1 (en) 2012-04-02 2013-04-01 Methods for improving diaphragm function

Publications (2)

Publication Number Publication Date
MX2014011881A MX2014011881A (es) 2016-07-20
MX354965B true MX354965B (es) 2018-03-27

Family

ID=49300969

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014011881A MX354965B (es) 2012-04-02 2013-04-01 Metodo para mejorar la funcion del diafragma.

Country Status (15)

Country Link
US (2) US20150065525A1 (enExample)
EP (1) EP2834269A4 (enExample)
JP (3) JP6345645B2 (enExample)
KR (1) KR20160046693A (enExample)
CN (2) CN108553467A (enExample)
AU (2) AU2013243671B2 (enExample)
BR (1) BR112014024552A2 (enExample)
CA (1) CA2868507A1 (enExample)
EA (1) EA031183B1 (enExample)
HK (1) HK1206364A1 (enExample)
IL (2) IL234885A0 (enExample)
MX (1) MX354965B (enExample)
PH (1) PH12014502217A1 (enExample)
SG (2) SG10201701101YA (enExample)
WO (1) WO2013151938A1 (enExample)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8299248B2 (en) 2006-08-02 2012-10-30 Cytokinetics, Incorporated Certain 1H-imidazo[4,5-b]pyrazin-2(3H)-ones and 1H-imidazo[4,5-b]pyrazin-2-ols and methods for their use
EP2560488B1 (en) 2010-04-23 2015-10-28 Cytokinetics, Inc. Certain amino-pyridines and amino-triazines, compositions thereof, and methods for their use
AR081626A1 (es) 2010-04-23 2012-10-10 Cytokinetics Inc Compuestos amino-piridazinicos, composiciones farmaceuticas que los contienen y uso de los mismos para tratar trastornos musculares cardiacos y esqueleticos
AR081331A1 (es) * 2010-04-23 2012-08-08 Cytokinetics Inc Amino- pirimidinas composiciones de las mismas y metodos para el uso de los mismos
WO2012178125A1 (en) 2011-06-22 2012-12-27 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase
CN109316480A (zh) 2011-07-13 2019-02-12 赛特凯恩蒂克公司 组合als疗法
BR112014025251B1 (pt) * 2012-04-11 2021-03-02 Fady Malik uso de um ativador de troponina de músculo esquelético e composição compreendendo o mesmo
LT3418281T (lt) 2012-12-07 2021-01-11 Vertex Pharmaceuticals Inc. Pirazolo[1,5-a]pirimidinai, naudotini kaip atr kinazės inhibitoriai, skirti vėžinių ligų gydymui
CA2903979A1 (en) 2013-03-14 2014-09-18 Novartis Ag 3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant idh
EP2970288A1 (en) 2013-03-15 2016-01-20 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase
EP2970289A1 (en) 2013-03-15 2016-01-20 Vertex Pharmaceuticals Inc. Compounds useful as inhibitors of atr kinase
WO2014143240A1 (en) 2013-03-15 2014-09-18 Vertex Pharmaceuticals Incorporated Fused pyrazolopyrimidine derivatives useful as inhibitors of atr kinase
HUE046727T2 (hu) 2013-12-06 2020-03-30 Vertex Pharma Az ATR-kináz inhibitoraként használható vegyület, 2-amino-6-fluoro-N-[5-fluoro-piridin-3-IL]-pirazolo-[1,5-A]-pirimidin-3-karboxamid, ennek elõállítása, különbözõ szilárd formái és ezek radioaktív nyomjelzett származékai
LT3137622T (lt) 2014-04-29 2022-04-25 Cytokinetics, Inc. Gyvybinio pajėgumo nykimo mažinimo būdai
ES2777608T3 (es) 2014-06-05 2020-08-05 Vertex Pharma Derivados radiomarcados de un compuesto de 2-amino-6-fluoro-N-[5-fluoro-piridin-3-il]-pirazolo[1,5-a]pirimidin-3-carboxamida útiles como inhibidores de ATR cinasa, la preparación de dicho compuesto y diferentes formas sólidas del mismo
US11179394B2 (en) 2014-06-17 2021-11-23 Vertex Pharmaceuticals Incorporated Method for treating cancer using a combination of Chk1 and ATR inhibitors
US9987279B2 (en) * 2014-09-09 2018-06-05 Astellas Pharma Inc. Pharmaceutical composition for prevention and/or treatment of urinary incontinence
WO2016193844A1 (en) 2015-05-29 2016-12-08 Pfizer Inc. Novel heterocyclic compounds as inhibitors of vanin-1 enzyme
US11464774B2 (en) 2015-09-30 2022-10-11 Vertex Pharmaceuticals Incorporated Method for treating cancer using a combination of DNA damaging agents and ATR inhibitors
SG11201806416XA (en) 2016-02-12 2018-08-30 Astellas Pharma Inc Tetrahydroisoquinoline derivatives
US10906888B2 (en) 2016-07-14 2021-02-02 Pfizer Inc. Pyrimidine carboxamides as inhibitors of Vanin-1 enzyme
JP7687968B2 (ja) 2019-06-19 2025-06-03 エフ． ホフマン－ラ ロシュ アーゲー デジタルバイオマーカー
CN114051390A (zh) * 2019-06-19 2022-02-15 豪夫迈·罗氏有限公司 数字生物标志物
JP7728184B2 (ja) 2019-06-19 2025-08-22 エフ． ホフマン－ラ ロシュ アーゲー デジタルバイオマーカー
TW202116754A (zh) 2019-07-11 2021-05-01 美商Ｅ 斯蓋普生物股份有限公司 作為ｌｒｒｋ２抑制劑之吲唑及氮雜吲唑
JP7825618B2 (ja) 2020-11-06 2026-03-06 サイトキネティックス， インコーポレイテッド 二環式１，４－ジアゼパノン及びその治療的使用
TW202329937A (zh) 2021-12-03 2023-08-01 美商英塞特公司 雙環胺ｃｋ１２抑制劑
US12084453B2 (en) 2021-12-10 2024-09-10 Incyte Corporation Bicyclic amines as CDK12 inhibitors
US20240382564A1 (en) * 2023-04-17 2024-11-21 Allysta Pharmaceuticals, Inc. Methods and Compositions for Treating Muscular Dystrophy and Memory Impairment

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070173465A9 (en) * 1995-10-11 2007-07-26 Monahan Sean D Expression of zeta negative and zeta positive nucleic acids using a dystrophin gene
AU6814901A (en) * 2000-06-01 2001-12-11 Univ North Carolina Methods and compounds for controlled release of recombinant parvovirus vectors
CN1283793C (zh) * 2002-06-03 2006-11-08 北京大学 具有骨骼肌刺激活性和免疫调节作用的趋化素样因子超家族
JP2007501805A (ja) * 2003-08-08 2007-02-01 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ ピリジルピペラジニルウレア
US8227603B2 (en) * 2006-08-01 2012-07-24 Cytokinetics, Inc. Modulating skeletal muscle
BRPI0714725B1 (pt) * 2006-08-02 2021-05-25 Cytokinetics, Inc Entidade química, composição farmaceuticamente aceitável, e, uso de uma entidade química
US8299248B2 (en) * 2006-08-02 2012-10-30 Cytokinetics, Incorporated Certain 1H-imidazo[4,5-b]pyrazin-2(3H)-ones and 1H-imidazo[4,5-b]pyrazin-2-ols and methods for their use
CN101821279A (zh) * 2007-08-15 2010-09-01 赛特凯恩蒂克公司 某些化学个体、组合物和方法
NL2001694C2 (en) * 2008-06-18 2009-12-22 Nasophlex B V Ear stimulator for producing a stimulation signal to an ear.
AR081331A1 (es) * 2010-04-23 2012-08-08 Cytokinetics Inc Amino- pirimidinas composiciones de las mismas y metodos para el uso de los mismos
AR081626A1 (es) * 2010-04-23 2012-10-10 Cytokinetics Inc Compuestos amino-piridazinicos, composiciones farmaceuticas que los contienen y uso de los mismos para tratar trastornos musculares cardiacos y esqueleticos

Also Published As

Publication number Publication date
WO2013151938A1 (en) 2013-10-10
BR112014024552A2 (pt) 2017-09-19
CN104379597A (zh) 2015-02-25
CA2868507A1 (en) 2013-10-10
CN108553467A (zh) 2018-09-21
PH12014502217A1 (en) 2015-01-12
EP2834269A1 (en) 2015-02-11
JP2018131460A (ja) 2018-08-23
IL267876A (en) 2019-09-26
EA201491605A1 (ru) 2015-03-31
EP2834269A4 (en) 2015-12-30
EA031183B1 (ru) 2018-11-30
JP2020147607A (ja) 2020-09-17
US20150065525A1 (en) 2015-03-05
IL234885A0 (en) 2014-12-31
AU2017272286A1 (en) 2018-01-04
IL267876B (en) 2021-03-25
AU2017272286B2 (en) 2019-05-09
KR20160046693A (ko) 2016-04-29
MX2014011881A (es) 2016-07-20
SG10201701101YA (en) 2017-04-27
SG11201406270YA (en) 2014-10-30
JP6345645B2 (ja) 2018-06-20
HK1206364A1 (en) 2016-01-08
JP2015516957A (ja) 2015-06-18
AU2013243671B2 (en) 2017-09-21
AU2013243671A1 (en) 2014-10-16
US20170266192A1 (en) 2017-09-21

Similar Documents

Publication Publication Date Title
PH12014502217A1 (en) Methods for improving diaphragm function
EA201270720A1 (ru) Модуляторы рецептора андрогенов и их применение
CA2900335C (en) Synthetic analogs of epipolythiodioxopiperazines and uses thereof
MX2013002422A (es) Sales de lorcaserina con acidos opticamente activos.
BR112015011933A2 (pt) composições bacterianas sinérgicas e métodos de produção e uso das mesmas
PH12014501997A1 (en) Esketamine for the treatment of treatment-refractory or treatment-resistant depression
EA201491617A1 (ru) Соединения для лечения спинальной мышечной атрофии
MX2013006040A (es) Antagonistas del receptor de acido lisofosfatidico y su uso en el tratamiento de fibrosis.
PE20150223A1 (es) Anticuerpos antagonistas mejorados contra factor-8 de crecimiento y diferenciacion y usos de los mismos
PH12014502286A1 (en) Improving resistance to skeletal muscle fatigue
EA201390799A1 (ru) Триазолопиридины
EA201491610A1 (ru) Модуляторы x рецепторов печени
PH12013500411A1 (en) Treatment of myocardial infarction using tgf - beta antagonists
PH12014500990A1 (en) Methods for treating gout flares
NZ709411A (en) New bacteria and consortia for the reduction of amonia and/or methane emission in manure or soil
MX364220B (es) Metodos de tratamientos de fibrosis.
MX2013004062A (es) Analogos de ciclosporina.
CO7160080A2 (es) Composiciones lipídicas de racecadotrillo
EA201491609A1 (ru) Модуляторы x рецепторов печени
EA201291329A1 (ru) Гетероциклические соединения, их получение и их терапевтическое применение
BR112013001932A2 (pt) estabilizador de solos contendo material carbonáceo e métodos para uso do mesmo
NZ713129A (en) Oxprenolol compositions for treating cancer
MX2013003599A (es) Interferon-beta para uso como monoterapia o en combinacion con otras terapias de cancer.
EA201391144A1 (ru) Композиции для обработки волос
EA201590232A1 (ru) Животная модель болезни краббе

Legal Events

Date Code Title Description
GB Transfer or rights

Owner name: CYTOKINETICS, INC.

FG Grant or registration